ReviewFrontiers of medicine2024
Progress on early diagnosing Alzheimer's disease.
Review in Frontiers of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Design of bifunctional pyridinophane ligands as MnInorganic chemistry frontiers · 2026Article
- Microbiota-Gut-Brain Axis Mechanisms in Cognitive Impairment Associated with Central Obesity.Current obesity reports · 2026Review
- Engineering Nanoplatforms for Alzheimer's Disease Detection via Biomolecular Corona Proteomic and Lipidomic Profiling.Advanced healthcare materials · 2026Article
- Clinical pathways matter for multimodal deep learning in early Alzheimer's disease detection.Scientific reports · 2026Article
- Longitudinal association between sarcopenia and comorbidity of mild cognitive impairment and depression among older adults in China: the moderating effect of non-obesity.BMC geriatrics · 2026Article
- Review
- NeuroFusion-ViT: A Hybrid CNN-EVA Transformer Model with Cross-Attention Fusion for MRI-Based Alzheimer's Stage Classification.Diagnostics (Basel, Switzerland) · 2026Article
- Catechins in insomnia-Alzheimer's disease comorbidity: A network pharmacology and molecular docking study.Medicine · 2026Article
- Advances in AI-based diagnosis of Alzheimer's disease using MRI: a comprehensive survey.Frontiers in medicine · 2026Review
- Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy.Frontiers in pharmacology · 2026Review
- From muscle to brain: the mediating effect of vitamin D in the relationship between muscle loss and cognitive function in Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Metabolic status and brain health: the relationship between the metabolic score for insulin resistance and cognitive function in older adults.European journal of medical research · 2025Article
- 1-Nitro-2-Phenylethane as a Multitarget Candidate for Cognitive and Psychiatric Disorders: Insights from In Silico and Behavioral Approaches.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Profiling characteristics of plasma exosomal miRNAs across cognitive stages: from normalcy to mild cognitive impairment and Alzheimer's disease.RSC advances · 2025Article
- Biomarker Profile in Peripheral Blood Cells Related to Alzheimer's Disease.Molecular neurobiology · 2025Article
- Integrated cerebellar radiomic-network model for predicting mild cognitive impairment in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Oxidative Stress-mediated Lipid Peroxidation-derived Lipid Aldehydes in the Pathophysiology of Neurodegenerative Diseases.Current neuropharmacology · 2025Review
- Review of FUNDC1-mediated mitochondrial autophagy in Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Multi-Index Brain Function-Cognition Correlation in Amnestic Mild Cognitive Impairment: A Resting-State fMRI Study.American journal of Alzheimer's disease and other dementiasArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects both cognition and non-cognition functions. The disease follows a continuum, starting with preclinical stages, progressing to mild cognitive and behavioral impairment, ultimately leading to dementia. Early detection of AD is crucial for better diagnosis and more effective treatment. However, the current AD diagnostic tests of biomarkers using cerebrospinal fluid and/or brain imaging are invasive or expensive, and mostly are still not able to detect early disease state. Consequently, there is an urgent need to develop new diagnostic techniques with higher sensitivity and specificity during the preclinical stages of AD. Various non-cognitive manifestations, including behavioral abnormalities, sleep disturbances, sensory dysfunctions, and physical changes, have been observed in the preclinical AD stage before occurrence of notable cognitive decline. Recent research advances have identified several biofluid biomarkers as early indicators of AD. This review focuses on these non-cognitive changes and newly discovered biomarkers in AD, specifically addressing the preclinical stages of the disease. Furthermore, it is of importance to explore the potential for developing a predictive system or network to forecast disease onset and progression at the early stage of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.